Clinical Trials Directory

Trials / Completed

CompletedNCT00226044

Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.

Rectal and Oral Omeprazole Treatment of Gastroesophageal Reflux in Infants With Esophageal Atresia or Congenital Diaphragmatic Hernia; A Pharmacodynamic and Pharmacokinetic Study.

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
17 (actual)
Sponsor
Rijnstate Hospital · Academic / Other
Sex
All
Age
6 Weeks – 3 Months
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare the efficacy of oral and rectal omeprazole treatment in infants with gastroesophageal reflux due to esophageal atresia or congenital diaphragmatic hernia.

Detailed description

Omeprazole is a highly effective drug for the treatment of gastroesophageal reflux disease (GERD) in infants. Infants, aged 0-12 months, require a non-standard dose of omeprazole. Due to this fact extemporaneous formulations of omeprazole are administered to these infants. The oral bioavailability of omeprazole in nonproprietary formulations may be unpredictable and produce variable degrees of drug exposure. The dose range for GERD management in pediatric studies using omeprazole is 0.3 - 3.5 mg/kg/day. Dosing information, aged-specific pharmacodynamic and pharmacokinetic data are not available in infants, aged 0-12 months. Two adult studies at healthy volunteers suggest that an omeprazole suppository is an effective dosage form.This study is designed to evaluate and to compare the efficacy, the pharmacodynamics and the pharmacokinetics of oral and rectal omeprazole treatment in infants with gastroesophageal reflux disease.

Conditions

Interventions

TypeNameDescription
DRUGOmeprazole rectally 1mg/kgA single dose of 1 mg/kg rectally administered omeprazole.

Timeline

Start date
2005-09-01
Primary completion
2016-09-01
Completion
2017-09-01
First posted
2005-09-26
Last updated
2019-10-07

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT00226044. Inclusion in this directory is not an endorsement.

Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants. (NCT00226044) · Clinical Trials Directory